netFormulary

Liraglutide Saxenda^®

Formulary

6mg/ml solution for injection 3ml pre-filled pens

liraglutide is recommended as an option in overweight and obesity as long as it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service

for NICE TA749 Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)

MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued

MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

NICE TA664: Liraglutide for managing overweight and obesity

Orlistat

Formulary

Capsules 120mg

MHRA: Orlistat: theoretical interaction with antiretroviral HIV medicines

Semaglutide Wegovy^®

Formulary

Solution for injection in pre filled pen

0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg

Only available via referral to a Tier 3 Weight Management Service.

for NICE TA910 Semaglutide for managing overweight and obesity in young people aged 12 to 17 years.

MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued

NICE TA875: Semaglutide for managing overweight and obesity

Tirzepatide Mounjaro®

Formulary

Pre-filled pens, solution for injection.

Managing overweight and obesity in secondary care.

Mounjaro® (Tirzepatide) has been reviewed by NICE for managing overweight and obesity (NICE TA1026) and will be made available to NHS patients according to the following stages:

1. Available by spring 2025 to all patients accessing specialist weight management services, and

2. Available by summer 2025 for a phased introduction of delivery to eligible cohorts, in line with NHS England’s interim commissioning policy, in primary care.

LSCMMG has agreed that the RAG status of tirzepatide for the management of overweight and obesity will reflect the availability of tirzepatide as defined by NICE and NHS England.

It is expected that the RAG position will be updated periodically and in line with the implementation plan.

LSCMMG: Tirzepatide - Managing overweight and obesity in secondary care

Tirzepatide Mounjaro^®

Formulary

Pre-filled pens, solution for injection.

Managing overweight and obesity in primary care.

Mounjaro® (Tirzepatide) has been reviewed by NICE for managing overweight and obesity (NICE TA1026) and will be made available to NHS patients according to the following stages:

1. Available by spring 2025 to all patients accessing specialist weight management services, and

2. Available by summer 2025 for a phased introduction of delivery to eligible cohorts, in line with NHS England’s interim commissioning policy, in primary care.

LSCMMG has agreed that the RAG status of tirzepatide for the management of overweight and obesity will reflect the availability of tirzepatide as defined by NICE and NHS England.

It is expected that the RAG position will be updated periodically and in line with the

implementation plan.

LSCMMG: Tirzepatide - Managing overweight and obesity in primary care

LSCMMG: Tirzepatide for managing overweight and obesity position statement